18584 Federal Register / Vol. 74, No. 77 / Thursday, April 23, 2009 / Notices 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel. PAR–08– 

261: Research on Emergency Medical 

Services for Children. 

Date: May 12–13, 2009. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: Suzanne Ryan, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3139, 

Bethesda, MD 20892. (301) 435–1712. 

ryansj@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences. Integrated Review Group. 

Oral, Dental and Craniofacial Sciences Study 

Section. 

Date: May 27–28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Hilton Alexandria Old Town, 

1767 King Street, Salon A/B, Alexandria, VA 

22314. 

Contact Person: Tamizchelvi Thyagarajan, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4016K, 

MSC 7814,Bethesda, MD 20892. 301–451– 

1327. tthyagar@csr.nih.gov. 

Name of Committee: Digestive, Kidney and 

Urological Systems. Integrated Review 

Group. Clinical and Integrative 

Gastrointestinal Pathobiology Study Section. 

Date: May 29, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Avenue Hotel Chicago, 160 E. Huron 

Street, Chicago, IL 60611. 

Contact Person: Mushtaq A. Khan, DVM, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2176, 

MSC 7818, Bethesda, MD 20892. 301–435– 

1778. khanm@csr.nih.gov. 

Name of Committee: Cardiovascular and 

Respiratory Sciences. Integrated Review 

Group. Lung Injury, Repair, and Remodeling 

Study Section. 

Date: June 2–3, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Warwick Seattle Hotel, 401 Lenora 

Street, Seattle, WA 98121. 

Contact Person: Ghenima Dirami, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4112, 

MSC 7814, Bethesda, MD 20892. 301–594– 

1321. diramig@csr.nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group. Molecular and 

Integrative Signal Transduction Study 

Section. 

Date: June 2, 2009. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, NW., Washington, DC 

20037. 

Contact Person: Raya Mandler, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5134, 

MSC 7840, Bethesda, MD 20892. (301) 402– 

8228. rayam@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience. 

Integrated Review Group. Neurobiology of 

Learning and Memory Study Section. 

Date: June 2–3, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, NW., Washington, DC 

20037. 

Contact Person: Bernard F. Driscoll, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892. (301) 435– 

1242. driscolb@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience. 

Integrated Review Group. Somatosensory and 

Chemosensory Systems Study Section. 

Date: June 2–3, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Avenue, NW., Washington, DC 20037. 

Contact Person: Daniel R. Kenshalo, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5182, 

MSC 7844, Bethesda, MD 20892. 301–435– 

1255. kenshalod@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 15, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9208 Filed 4–22–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, Non-Human Primate 

Reagent Resource. 

Date: May 14, 2009. 

Time: 1:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

3200, Bethesda, MD 20817. 

Contact Person: Ellen S. Buczko, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–2676, 

ebuczko1@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: April 17, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9349 Filed 4–22–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Board on Radiation and 

Worker Health (ABRWH or Advisory 

Board), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), and pursuant to the 

requirements of 42 CFR 83.15(a), the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the 

aforementioned committee: 

Board Meeting Times and Dates (All times 

are Mountain Time): 

9 a.m.–5 p.m., May 12, 2009. 

9 a.m.–3:45 p.m., May 13, 2009. 

Public Comment Times and Dates (All 

times are Mountain Time): 

7 p.m.–8 p.m., May 12, 2009. 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 74, No. 77 / Thursday, April 23, 2009 / Notices 18585 

4 p.m.–5 p.m., May 13, 2009. 

Place: Holiday Inn Amarillo Hotel, 1911 I– 

40 East, Amarillo, TX 79102; Phone: (806) 

372–8741; Fax: (806) 372–7045. Audio 

Conference Call via FTS Conferencing. The 

USA toll-free dial-in number is 1–866–659– 

0537 with a pass code of 9933701. 

Status: Open to the public, limited only by 

the space available. The meeting space 

accommodates approximately 100 people. 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation Program 

(EEOICP) Act of 2000 to advise the President 

on a variety of policy and technical functions 

required to implement and effectively 

manage the new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines which 

have been promulgated by the Department of 

Health and Human Services (HHS) as a final 

rule; advice on methods of dose 

reconstruction which have also been 

promulgated by HHS as a final rule; advice 

on the scientific validity and quality of dose 

estimation and reconstruction efforts being 

performed for purposes of the compensation 

program, and advice on petitions to add 

classes of workers to the Special Exposure 

Cohort (SEC). 

In December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, which 

subsequently delegated this authority to the 

CDC. NIOSH implements this responsibility 

for CDC. The charter was issued on August 

3, 2001, renewed at appropriate intervals, 

and will expire on August 3, 2009. 

Purpose: This Advisory Board is charged 

with (a) providing advice to the Secretary, 

HHS, on the development of guidelines 

under Executive Order 13179; (b) providing 

advice to the Secretary, HHS, on the 

scientific validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at any 

Department of Energy facility who were 

exposed to radiation but for whom it is not 

feasible to estimate their radiation dose, and 

on whether there is reasonable likelihood 

that such radiation doses may have 

endangered the health of members of this 

class. 

Matters To Be Discussed: The agenda for 

the Advisory Board meeting includes: NIOSH 

Program Status Update; Department of Labor 

(DOL) Update; Department of Energy (DOE) 

Update; Board Security Plan; Special 

Exposure Cohort (SEC) Petitions for: Linde 

Ceramics Plant (Residual Period); Standard 

Oil Development Company of New Jersey; 

Blockson Chemical Company (radon-related 

dose reconstruction); and Dow Chemical 

Company (Madison, Illinois); Special 

Exposure Cohort (SEC) Petition Status 

Updates; Work Group reports; Reports of the 

Subcommittees on Dose Reconstruction 

Reviews and Procedures Reviews; and Board 

Future Plans and Meetings. 

The agenda is subject to change as 

priorities dictate. 

In the event an individual cannot attend, 

written comments may be submitted 

according to the policy provided below. Any 

written comments received will be provided 

at the meeting and should be submitted to 

the contact person below well in advance of 

the meeting. 

Policy on Redaction of Board Meeting 

Transcripts (Public Comment), (1) if a person 

making a comment gives his or her name, no 

attempt will be made to redact that name. (2) 

NIOSH will take reasonable steps to ensure 

that individuals making public comment are 

aware of the fact that their comments 

(including their name, if provided) will 

appear in a transcript of the meeting posted 

on a public Web site. Such reasonable steps 

include: (a) A statement read at the start of 

each public comment period stating that 

transcripts will be posted and names of 

speakers will not be redacted; (b) A printed 

copy of the statement mentioned in (a) above 

will be displayed on the table where 

individuals sign up to make public comment; 

(c) A statement such as outlined in (a) above 

will also appear with the agenda for a Board 

Meeting when it is posted on the NIOSH Web 

site; (d) A statement such as in (a) above will 

appear in the Federal Register Notice that 

announces Board and Subcommittee 

meetings. (3) If an individual in making a 

statement reveals personal information (e.g., 

medical information) about themselves that 

information will not usually be redacted. The 

NIOSH FOIA coordinator will, however, 

review such revelations in accordance with 

the Freedom of Information Act and the 

Federal Advisory Committee Act and if 

deemed appropriate, will redact such 

information. (4) All disclosures of 

information concerning third parties will be 

redacted. (5) If it comes to the attention of the 

Designated Federal Officer (DFO) that an 

individual wishes to share information with 

the Board but objects to doing so in a public 

forum, the DFO will work with that 

individual, in accordance with the Federal 

Advisory Committee Act, to find a way that 

the Board can hear such comments. 

Contact Person for More Information: 

Theodore Katz, M.P.A., Executive Secretary, 

NIOSH, CDC, 1600 Clifton Road, MS E–20, 

Atlanta, GA 30333, Telephone (513)533– 

6800, Toll Free 1(800) CDC–INFO, e-mail 

ocas@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: April 16, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–9332 Filed 4–22–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Public Teleconference Regarding 

Licensing and Collaborative Research 

Opportunities for: A Double-Barreled 

Attack: Azatoxins, A New Hope for 

Treating Cancer 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

Technology Summary 

This technology describes a novel 

class of Topoisomerase II (top2) 

inhibitors that are useful in treating 

cancer. Drugs that inhibit the top2 

enzyme are among the most active 

anticancer agents discovered. However, 

many of the currently available 

inhibitors produce toxic side effects, 

have poor pharmacokinetics, or 

eventually become ineffective because 

malignant cells readily acquire 

resistance. Therefore, there is a need for 

developing new top2 inhibitor drugs 

that will overcome these limitations. 

Azatoxin and its derivatives, which 

are derived by combining two parent 

compounds etoposide and ellipticine, 

are the first compounds rationally 

designed as inhibitors of top2. 

Azatoxins are also potent inhibitors of 

tubulin polymerization. These two anticancer activities can be successfully 

separated by synthesizing azatoxin 

derivatives to yield compounds which 

can be pharmacologically advantageous 

against tumor proliferation. The 

azatoxin platform represents an 

unexploited class of top2 inhibitors that 

could be developed into especially 

potent chemotherapeutics. 

Competitive Advantage of Our 

Technology 

Currently, several top2 inhibitors are 

approved for clinical use; however, they 

produce serious side effects. Etoposide, 

for example, causes problems with 

myelosuppression, drug resistance, and 

has poor bioavailability. Moreover, it 

appears to have carcinogenic properties 

as it has been linked to the development 

of acute myelogenous leukemia—an 

effect also observed with mitoxantrone. 

Anthracyclines, like doxorubicin, have 

the same limitations as etoposide, but 

they also possess cardiotoxic effects. 

Azatoxins have the potential to be 

developed into chemotherapeutics that 

outperform these currently used top2 

inhibitors. 

Azatoxins have been substantially 

characterized through years of preclinical research demonstrating that 


sroberts on PROD1PC70 with NOTICES